Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With LOGEX Healthcare Analytics Amsterdam The Netherlands.
Phase
—
Status
Completed
Study type
Observational
Enrollment
217actual
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-06 | actual | When the study began enrolling |
| Primary completion | 2025-11-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-25 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemorrhage
Intervention
- Drug: Andexanet alfa
Primary outcome
what the primary-completion date above is the date OFPatient characteristics
measured Baseline (which is the date andexanet alfa is administered, i.e. indexdate)
Publications
- PMID 32618210 — cited as background
- PMID 35710578 — cited as background
- PMID 35280921 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed